Toxicity study of erucylphosphocholine in a rat model

Current Eye Research

Volumn 30, Issue 9, 2005, Pages 813-820

  Schuettauf, Frank ^a   Eibl, Kirsten H ^b   Thaler, Sebastian ^a   Shinoda, Kei ^a   Rejdak, Robert ^c   May, C Albrecht ^d   Blatsios, Georgios ^a   Welge Lussen, Ulrich ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Animal model; Electroretinography; Intravitreal drug delivery; Retinal cells; Vitreoretinal pharmacology

Indexed keywords

BALANCED SALT SOLUTION; CHOLINE DERIVATIVE; ERUCYLPHOSPHOCHOLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE SEGMENT; ARTICLE; CHOROID; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG STRUCTURE; ELECTRON MICROSCOPY; ELECTRORETINOGRAPHY; EYE TOXICITY; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MUELLER CELL; NONHUMAN; OPHTHALMOSCOPY; PIGMENT EPITHELIUM; POSTERIOR EYE CHAMBER; PRIORITY JOURNAL; RAT; RETINA; RETINA GANGLION CELL; SLIT LAMP; TOXICITY TESTING;

ANIMALS; CELL COUNT; CHOROID; ELECTRORETINOGRAPHY; INJECTIONS; MALE; PHOSPHORYLCHOLINE; PIGMENT EPITHELIUM OF EYE; RATS; RATS, INBRED BN; RETINA; VITREOUS BODY;

EID: 26444562363     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680591006093     Document Type: Article

References (31)

1. Eibl H, Unger C. Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat Rev. 1990;17:233-242.
2. Hilgard P, Engel J. Clinical aspects of miltefosine and its topical formulation Miltex®. Drugs Today. 1994;30 (Suppl. B):3-81.
3. Leonard R, Hardy J, van Tienhoven G, Houston S, Simmonds P, David M, Mansi J. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol. 2001;21:4150-4159.
4. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother. 1992;36:1630-1634.
5. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002;347:1739-1746.
6. Kötting J, Berger MR, Unger C, Eibl H. Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations. Cancer Chemother Pharmacol. 1992;30:105-112.
7. Sobottka SB, Berger MR, Eibl H. Structure-activity relationships of four anticancer alkylphosphocholine derivatives in vitro and in vivo. Int J Cancer. 1993;53:418-425.
8. Eibl KH, Banas B, Schoenfeld CL, Neubauer AS, Priglinger S, Kampik A, Welge-Luessen U. Alkylphosphocholines inhibit proliferation of human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2003;44:3556-3561.
9. Hiscott PS, Grierson I, McLeod D. Retinal pigment epithelial cells in epiretinal membranes: an immunohistochemical study. Br J Ophthalmol. 1984;68:708-715.
10. Hiscott P, Sheridan C, Magee RM, Grierson I. Matrix and the retinal pigment epithelium in proliferative retinal disease. Prog Retin Eye Res. 1999;18:167-190.
11. Asaria RHY, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, Aylward GW. Adjuvant 5-fluouracil and heparin prevents proliferative vitreoretinopathy. Ophthalmology. 2001;108:1179-1183.
12. Zheng B, Oishi K, Shoji M, Eibl H, Berdel WE, Hajdu J, Vogler WR, Kuo JF. Inhibition of protein kinase C, (sodium plus potassium)-activated adenosine triphosphatase, and sodium pump by synthetic phospholipid analogues. Cancer Res. 1990;50:3025-3031.
13. Shoji M, Raynor RL, Fleer EAM, Eibl H, Vogler WR, Kuo JF. Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells. Lipids 1991;26:145-149.
14. Überall F, Oberhuber H, Maly K, Zaknun J, Demuth L, Grunicke HH. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res. 1991;51:807-812.
15. Nishizuka Y. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science. 1992;258:607-614.
16. Erdlenbruch B, Jendrossek V, Gerriets A, Vetterlein F, Eibl H, Lakomek M. Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. Cancer Chemother Pharmacol. 1999;44:484-490.
17. Cannon JP, Fiscella R, Pattharachayakul S, Garey KW, De Alba F, Piscitelli S, Edward DP, Danziger LH. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. Invest Ophthalmol Vis Sci. 2003;44:2112-2117.
18. Maia M, Margalit E, Lakhanpal R, Tso MO, Grebe R, Torres G, Eong KG, Farah ME, Fujii GY, Weiland J, et al. Effects of intravitreal indocyanine green injection in rabbits. Retina. 2004;24:69-79.
19. Rowley SA, Vijayasekaran S, Yu PK, McAllister IL, Yu DY. Retinal toxicity of intravitreal tenecteplase in the rabbit. Br J Ophthalmol. 2004;88:573-578.
20. Sun Q, Ooi VE, Chan SO. N-methyl-D-aspartate-induced excitotoxicity in adult rat retina is antagonized by single systemic injection of MK-801. Exp Brain Res. 2001;138:37-45.
21. Macky TA, Oelkers C, Rix U, Heredia ML, Kunzel E, Wimberly M, Rohrer B, Crosson CE, Rohr J. Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of y novel mitomycin C-triamcinolone acetonide conjugate. J Med Chem. 2002;45:1122-1127.
22. Enaida H, Sakamoto T, Hisatomi T, Goto Y, Ishibashi T. Morphological and functional damage of the retina caused by intravitreous indocyanine in rat eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240:209-213.
23. Chidlow G, Osborne NN. Rat retinal ganglion cell loss caused by kainate, NMDA and ischemia correlated with a reduction in mRNA and protein of Thy-1 and neurofilament light. Brain Res. 2003;963:298-306.
24. Rejdak R, Zarnowski T, Turski WA, Kocki T, Zagorski Z, Zrenner E, Schuettauf F. Alterations of kynurenic acid content in the retina in response to retinal ganglion cell damage. Vision Res. 2003;43:497-503.
25. Dalke C, Löster J, Fuchs H, Gailus-Durner V, Soewarto D, Favor J, Neuhäuser-Klaus A, Pretsch W, Gekeler F, Shinoda K, et al. Electroretinography as a screening method for mutations causing retinal dysfunction in mice. Invest Ophthalmol Vis Sci. 2004;45:601-609.
26. Schuettauf F, Naskar R, Vorwerk CK, Zurakowski D, Dreyer EB. Ganglion cell loss after optic nerve crush mediated through AMPA-Kainate and NMDA receptors. Invest Ophthalmol Vis Sci. 2000;41:4313-4316.
27. Seme MT, Summerfelt P, Neitz J, Eells JT, Henry MM. Differential recovery of retinal function after mitochondrial inhibition by methanol intoxication. Invest Ophthalmol Vis Sci. 2001;42:834-841.
28. Goto W, Ota T, Morikawa N, Otori Y, Hara H, Kawazu K, Miyawaki N, Tano Y. Protective effects of timolol against the neuronal damage induced by glutamate and ischemia in the rat retina. Brain Res. 2002;958:10-19.
29. Yoneda S, Tanaka E, Goto W, Ota T, Hara H. Topiramate reduces excitotoxic and ischemic injury in the rat retina. Brain Res. 2003;967:257-266.
30. Goto Y, Taniwaki T, Shigematsu J, Tobimatsu S. The long-term effects of antiepileptic drugs on the visual system in rats: electrophysiological and histopathological studies. Clinic Neurophysiol. 2003;114:1395-1402.
31. Theischen M, Bornfeld N, Becher R, Keller U, Wessing A. Hexadecylphosphocholine may produce reversible functional defects of the retinal pigment epithelium. Ger J Ophthalmol. 1993;2:113-115.